Bemolan

Quick links to important sections

Bemolan

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bemolan

Property Description
Active ingredient Magaldrate
Form Tablets, Oral Suspension, Oral Gel
Pharmacological class Antacid / Gastric Acid Neutralizer
Common purpose Symptomatic relief of hyperacidity
Origin Synthetic hydroxymagnesium aluminate complex

Bemolan is a pharmaceutical preparation containing the single active ingredient Magaldrate, specifically utilized for the management of symptoms arising from excessive acidity within the stomach.

What Type of Medication is Bemolan (Magaldrate)?

Bemolan is classified as an antacid and a gastric acid neutralizer, belonging to the pharmacological group of Drugs for acid related disorders (ATC code A02AD02). Its fundamental purpose is to provide rapid, symptomatic relief for common conditions associated with hyperacidity, such as heartburn and general acid indigestion. Magaldrate functions as an antacid agent for managing acid-related symptoms. This single active ingredient product is often available over-the-counter (OTC) in several regions, facilitating quick access for adults experiencing temporary discomfort.

Composition, Forms, and Chemical Origin

The medication's effectiveness is rooted in its active component, Magaldrate, which is a synthetic compound derived from inorganic salts. Chemically, it is defined as a hydroxymagnesium aluminate complex. This unique complex structure involves the combined salts of aluminium and magnesium, contributing to its balanced action. Bemolan is designed for oral intake, and its common dosage form(s) include liquid presentations, such as oral suspension and oral gel, as well as solid tablets.

High-Level Principle of Action and General Benefit

The high-level principle of action is direct acid neutralization within the stomach, which rapidly corrects the gastric pH imbalance. Due to its buffering capacity, Magaldrate chemically reacts with stomach acid to reduce its concentration, providing quick comfort and minimizing irritation. This specific mechanism is beneficial because, in addition to neutralizing acid, the change in environment supports the inactivation of pepsin, a digestive enzyme that can contribute to mucosal irritation during periods of sour stomach and acid indigestion.

What side effects are possible with Bemolan?

Possible Side Effects and Safety Information

The officially documented safety profile of Bemolan (Magaldrate) details potential adverse reactions categorized by the body systems they may affect. The most frequently observed reactions are localized to the digestive tract and are generally mild.

Adverse Reactions by System-Organ Class

The regulatory labeling confirms potential effects primarily within the Gastrointestinal Disorders class, which include the occurrence of loose stools or diarrhea (associated with the magnesium component) and constipation (associated with the aluminum component), as well as occasional stomach cramps.

More serious, systemic reactions are documented under Metabolism and Nutrition Disorders, Musculoskeletal and Connective Tissue Disorders, and Nervous System Disorders.

Serious Adverse Reactions and Safety Constraints

The serious safety concerns documented in regulatory information are explicitly linked to the accumulation of the medicine's components, particularly with prolonged or chronic use. These systemic risks include Hypophosphatemia (phosphate depletion) and Hyperaluminemia (aluminum accumulation), which may lead to conditions such as Osteomalacia (bone softening) and Neurotoxicity (including encephalopathy).

Due to the critical risk of component accumulation, official labeling mandates safety restrictions for certain populations. The medicine is contraindicated in individuals with severe renal impairment because the inability of the kidneys to adequately eliminate the magnesium and aluminum components significantly increases the risk of serious systemic toxicity. Official safety notes also advise against prolonged, high-dose use to mitigate the risk of these cumulative effects.

Overdose and Emergency Response

The official overdose profile for Bemolan (Magaldrate) focuses on the potential for systemic toxicity arising from its active components and the mandated emergency response.

Overdose Scope

Property Statement Derived from Official Regulatory Documents
Documented overdose presentations: Exaggeration of gastrointestinal effects, including severe diarrhea, constipation, vomiting, abdominal pain, and abdominal distension.
Physiological systems affected (as stated in label): Electrolyte balance (Hypermagnesemia, Hyperaluminemia, Hypophosphatemia), Renal system, Gastrointestinal system.
Dose-related or exposure-related factors (if applicable): Risk increases following large doses or prolonged, chronic use, particularly if exceeding the maximum authorized dosage.
Population-specific overdose notes (if applicable): Patients with renal impairment (kidney disease) are at significantly higher risk of severe systemic toxicity, necessitating specific monitoring and intervention.
Emergency-response statements (as written in official documents): Treatment is to be symptomatic and general supportive measures must be utilized.
When immediate medical help is required (label-derived phrasing only): Seek emergency medical attention immediately if overdose is suspected or for the onset of severe, persistent symptoms. Contact Poison Control for guidance.

Overdose Classifications (High-Level)

Property Statement Derived from Official Regulatory Documents
Severity classification (as defined in official documents): Acute overdose is generally classified as unlikely to cause serious systemic effects; however, severe systemic outcomes are possible in susceptible patients.
Regulatory basis (EMA / FDA / etc.): US Code of Federal Regulations (OTC Antacid Monograph) and European Summary of Product Characteristics.
Overdose-context constraints (as defined in official documents): Severe toxicity risk is principally constrained by the body’s ability to excrete accumulated aluminum and magnesium ions.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may present with severe gastrointestinal disturbances, including abdominal pain, vomiting, and diarrhea or constipation.
  • The most serious documented consequences involve systemic mineral accumulation, leading to states of Hypermagnesemia and Hyperaluminemia.
  • Hypophosphatemia is a documented metabolic effect of prolonged excessive exposure.
  • In patients with renal impairment, excessive exposure carries the risk of severe complications, including the potential need for haemodialysis or peritoneal dialysis to eliminate accumulated ions.
  • No specific antidote is formally listed in the regulatory documents.

Connection to the overall overdose profile: Regulatory documents define the Magaldrate overdose profile by focusing on the acute GI symptoms and the high-risk scenario of systemic mineral accumulation. This structure mandates seeking emergency medical attention when severe symptoms arise or when an overdose is suspected, acknowledging that supportive care and clinical monitoring, particularly for electrolyte balance, are the required management steps.

Therapeutic Uses of Bemolan

Bemolan (Magaldrate) is applied across therapeutic domains where additional symptomatic support is needed, primarily focusing on symptoms related to physical discomfort and irritation linked to symptoms of heightened physiological activity (excessive stomach acid). Generally, it helps address symptom clusters that may appear suddenly or fluctuate due to diet, stress, or underlying conditions. The medication is utilized in the management of conditions such as gastroesophageal reflux, esophagitis, and certain gastric ulcers.

The medication is commonly used to help with symptoms of heartburn (pyrosis), general acid indigestion, and the distress of a sour stomach. It is relevant in clinical settings that involve acute or unstable symptom patterns, such as flare-ups in gastritis and peptic ulcer disease. The core benefit is the symptomatic relief it provides, and it assists with maintaining functional stability when symptoms interfere with routine activities. It is generally used in situations where patients experience burning or discomfort and require assistance in symptomatic relief for symptom stabilization.


Quick Fact: Applied for symptoms of Episodic Burning

Eligibility and Restrictions for Use

Bemolan (Magaldrate) eligibility is strictly defined by regulatory bodies to manage risks associated with its aluminum and magnesium components. Use of this medicine is classified into three categories: Contraindicated, Conditional Use, and Not Established.

Contraindications (Must Not Use)

The medicine is contraindicated and must not be used by individuals with a known hypersensitivity or allergy to Magaldrate or its components. Due to the risk of systemic accumulation, use is also prohibited for patients diagnosed with severe renal impairment or kidney failure. Formal non-eligibility also includes patients with Hypophosphataemia (low blood phosphate levels) or severe debilitation.

Age-Group Eligibility

Bemolan is approved for standard use in adults. For the pediatric population, the medicine's safety and efficacy are not established in children younger than 12 years, and use in this age group requires specific professional direction. Older adults generally follow the adult guidelines unless co-existing renal impairment is present.

Conditional Use Populations

Specific physiological states and chronic conditions require caution or professional consultation before use. Use is not recommended during pregnancy or lactation unless the benefits are deemed necessary, as data is limited. Caution is also advised for patients with certain comorbidities, including Alzheimer's dementia or pre-existing severe gastrointestinal issues like a blockage.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Bemolan

Interaction Scope

Property Value
Medicinal product categories with documented interactions Antibiotics (Fluoroquinolones, Tetracyclines), Anticoagulants, Bisphosphonates, Thyroid Hormones, Antifungals, H2-Antagonists, and Supplements containing Iron or Citrate.
Specific interacting medicines (if explicitly listed) Levodopa, Digoxin, Indomethacin, Dicumarol, Chlorpromazine, Isoniazid, Phenytoin, Ketoconazole, Itraconazole, and Levothyroxine.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic interference via reduced absorption (due to binding or altered gastric pH) and pharmacodynamic interaction (e.g., potentialization of anticoagulant effects).
Timing-based interaction rules (if applicable) Co-administration with most oral products must be separated by one to two hours. Enteric-coated drugs require a separation of at least one hour.
Population-specific interaction notes (if applicable) Patients with severe renal impairment/failure face an increased risk of aluminum and magnesium systemic accumulation and related toxicity due to reduced clearance.
Interaction-related restrictions The co-administration of Tetracycline-containing antibiotics is formally restricted or prohibited in some national regulatory labels.

Interaction Classifications (High-Level)

Classification Value
Interaction severity classification (as defined in official documents) Contraindicated (with certain antibiotics in some regions); Clinically Significant (absorption reduction for multiple drug classes; systemic accumulation risk).
Regulatory basis (EMA / FDA / etc.) Based on government drug labels and monographs.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with Fluoroquinolone and Tetracycline antibiotics, Bisphosphonates, and Thyroid Hormones may lead to reduced systemic exposure and decreased efficacy of the co-administered drug.
  • The antacid may increase the absorption and serum concentration of Levodopa, while co-administration with Citrate-containing supplements is documented to increase systemic aluminum absorption.
  • Concomitant use with Cumarin derivatives (anticoagulants) may result in a potentialization of the anticoagulant effects.

Connection to the overall interaction profile (2–4 sentences): The regulatory documentation defines Magaldrate's interaction structure primarily as a function of absorption-based pharmacokinetic interference, which necessitates strict timing separation rules for a wide variety of essential medicinal products. This profile formally documents a minority of interactions that result in increased exposure and identifies combinations with formal prohibitions based on a high risk of therapeutic failure.

Mechanism of Action

Direct Chemical Buffering and pH Regulation

The core mechanism involves the non-systemic, chemical neutralization of excess Gastric Hydrochloric Acid ( HCl) within the stomach lumen. The active component, Magaldrate, rapidly consumes free acid molecules, raising the localized gastric pH into a buffered, neutral range. This immediate chemical reaction constitutes the molecular basis for the drug's swift onset kinetics and decreases the concentration of aggressive chemical species in the gastric environment.


Inactivation of Enzymes and pH Dependent Modulation

The mechanism extends beyond HCl to influence factors that contribute to gastric mucosal barrier integrity. The pH elevation causes the inactivation of the enzyme Pepsin, rendering it functionally inert. Additionally, the compound physically binds and adsorbs mucosal irritants like Bile Acids and Lysolecithin. This multi-factor approach to aggression control contributes to the maintenance of a stabilized luminal pH and reduced irritant concentration.


Mechanistic Constraints and Effect Duration

The functional duration of this mechanism is strictly localized and peripheral, dependent entirely on the drug's physical presence in the stomach lumen. The effect terminates when the non-systemic compound is cleared from the stomach during the process of gastric emptying. The buffering capacity is also limited by the need for acid ( HCl) to be present to trigger the full activation of the magaldrate complex.

Dosage and Administration Information

Administration Guidelines

Bemolan, which contains the active ingredient Magaldrate, is administered through the oral route. The medicine is commonly available in formulations such as oral suspension, oral gel, and tablets.


Dosing and Scheduling

Feature General Instructions
Standard Adult Dose Typically 540 mg to 1080 mg (equivalent to 5–10 mL of suspension) per dose, taken for symptomatic relief.
Maximum Daily Dose The total quantity administered must not exceed 80 mL (16 teaspoonfuls) within a 24-hour period.
Timing Relative to Meals Usually taken between meals and at bedtime or after meals and at bedtime.
Duration of Use Continuous use must not exceed 14 days without consultation from a healthcare professional.

Procedural and Contextual Instructions

Preparation steps are associated with proper administration. Liquid and suspension forms are shaken well immediately before measuring the dose. Doses are measured with a specially marked measuring spoon or cup to maintain accuracy, and doses of chewable tablets are thoroughly chewed before swallowing.

For oral liquid forms, the dose is followed with a full glass of water. To prevent the potential impact on the absorption of other medications, the product is generally not taken within 1 to 2 hours before or after other orally administered drugs. Use in children under 12 years is typically restricted or requires direction from a physician.

These administration guidelines describe the time-bound and dosage-constrained procedure for taking Magaldrate.

Recent Clinical Evidence

Recent Clinical Evidence

The clinical evidence for Bemolan (magaldrate) primarily focuses on its established use as an antacid to help manage symptoms related to stomach acid, such as heartburn, indigestion, and acid reflux.

Summary of Study Results

Research has explored the role of magaldrate, the active substance in Bemolan, in neutralizing stomach acidity. Magaldrate is chemically formulated to be a combination of aluminum and magnesium salts, allowing it to regulate stomach acid levels once it reaches the stomach.

  • Symptom Management: Studies evaluating magaldrate formulations have examined their ability to provide symptomatic relief for occasional gastric discomfort related to hyperacidity and burning. These studies focus on the reduction of these symptoms shortly after administration.
  • Mechanism Assessment: Research explores how magaldrate acts locally within the digestive system, where it is transformed into its component salts to help balance pH levels.

Safety and Tolerability Data

Clinical trials and post-marketing surveillance have monitored the tolerability of magaldrate. The side effects observed are generally mild and transient, with gastrointestinal effects being the most frequently noted.

  • Gastrointestinal Events: Events frequently reported in studies, particularly at higher doses, include constipation and diarrhea. At recommended doses, these manifestations are reported less often.
  • Risk Profile: Overall, the data collected regarding tolerability aligns with the known profile of an antacid medication used for short-term, symptomatic relief. No definitive conclusions are yet established across all subgroups, and the focus remains on assessing its short-term use for occasional acid-related discomfort.

Frequently Asked Questions (FAQ)

Common questions about Bemolan (FAQ)


Q: How fast should I expect Bemolan to start showing any noticeable effect?

Official information describes this medicine as having swift onset kinetics. Reports based on studies suggest that the acid-neutralizing effect may begin in as little as 30 minutes, though individual experiences may vary. This immediate chemical reaction is designed to provide quick symptomatic relief for hyperacidity.


Q: What is the general duration of Bemolan's effect after a single dose?

The functional duration of the medicine is strictly localized to the stomach. Official regulatory data generally reports that the maximum neutralizing action after a single dose lasts for about four hours. The effect terminates when the active substance is cleared from the stomach during the process of gastric emptying.


Q: What information is available regarding Bemolan's potential effects on the liver or kidneys?

Official information advises caution is required for patients with existing hepatic (liver) or renal (kidney) disease. Due to the risk of component accumulation, the medicine is formally contraindicated (must not be used) in individuals diagnosed with severe renal impairment or kidney failure.


Q: Are there known interactions between Bemolan and blood pressure or heart medications?

Yes, official documents mention that the medicine may interact with certain medications for high blood pressure, such as anti-hypertensives and beta-blockers. This type of interaction typically requires a specific timing separation rule (e.g., 1–2 hours) as a general rule to help mitigate interference with the absorption of the co-administered drug.


Q: What is the official risk classification for Bemolan use during pregnancy?

Regulatory information states that the medicine has not been formally assigned to a standard FDA pregnancy risk category. Its use during pregnancy is therefore only recommended when a health professional determines that the potential benefit is greater than any potential risk.


Q: Can women who are breastfeeding use Bemolan according to regulatory guidelines?

Official warnings state there are currently no available data on whether the components of the medicine are excreted into human breast milk. Due to this lack of data, caution is advised and the use of the medicine is typically considered on a conditional basis.


Q: How is Bemolan generally different from other common treatments for the same condition?

The medicine's active substance, Magaldrate, is chemically defined as a hydroxymagnesium aluminate complex. This is a synthetic structure that combines both magnesium and aluminum salts into one compound, whose structure combines both magnesium and aluminum salts for acid neutralization.


Q: Is Bemolan available as a generic version?

The active substance, Magaldrate, is the globally recognized generic (INN) name for the compound. Therefore, while Bemolan is a brand name, the active ingredient is available in different products under various names in different regions.


Q: Is it considered normal if a patient does not feel any different after the first few days on Bemolan?

Official product warnings state that if symptoms do not begin to improve, or if they worsen while taking the medicine, a health professional should be consulted. This is because the medicine is typically intended to provide symptomatic relief within a short timeframe.


Q: Does Bemolan have a known tendency to cause weight gain or weight loss?

Regulatory documents list ongoing loss of appetite and weight loss as reported serious adverse reactions. This type of reaction is not generally listed as a common or minor side effect.


Q: Are there any listed side effects of Bemolan that affect sleep or energy levels?

One reported non-gastrointestinal adverse reaction in regulatory documents is malaise, which is a general feeling of being unwell or low energy. Effects on sleep, such as insomnia or drowsiness, are not explicitly documented as common side effects.


Q: What are the general warnings about driving or operating machinery while taking Bemolan?

Regulatory-aligned information indicates the medicine usually does not affect a person’s ability to drive or operate machinery. If any adverse reactions are experienced, these should be taken into consideration before operating machinery.


Q: Is there any information about the potential for physical or psychological dependence on Bemolan?

Patient information consistently indicates that the drug is not considered to be habit-forming or associated with a risk of physical or psychological dependence.


Q: What common over-the-counter pain relievers or fever reducers interact with Bemolan?

A check of regulatory interaction data indicates that no interaction was found between the active substance and the common OTC pain reliever and fever reducer, Paracetamol (Acetaminophen). However, the general 1- to 2-hour separation rule remains relevant for this and most other oral medications.


Q: What is the official guidance on consuming alcohol while taking Bemolan?

Regulatory-aligned warnings indicate that the use of alcohol is advised against while using the medicine. This is because alcohol intake is known to stimulate the production of stomach acid, which can directly counter the medicine's acid-neutralizing effect.


Q: Are there any specific foods or beverages that should be avoided when using Bemolan?

While the official labeling does not list formal prohibitions for general foods, patient information often references avoiding items known to naturally increase stomach acidity. These often include high-fat foods, spicy items, and citrus fruits.


Q: Can people with pre-existing heart conditions safely use Bemolan?

Regulatory documents indicate that caution is required for use in patients with pre-existing conditions such as hypertension (high blood pressure) or other cardiovascular diseases. These conditions are listed as requiring careful consideration.


Q: Is Bemolan safe for patients with diabetes?

Official regulatory information advises that caution is necessary for use in patients with pre-existing diabetes mellitus. The presence of this condition is listed as requiring caution in official documents.


Q: Is it safe for someone with a history of seizures to take Bemolan?

Regulatory documents advise that caution is necessary for use in patients with a history of epilepsy (seizure disorder). This condition is listed as requiring careful consideration.


Q: What is the generally suggested action if a dose of Bemolan is accidentally missed?

General patient information for the medicine includes guidance on how to manage a missed dose. This guidance emphasizes the safety principle that two doses should never be taken at the same time.


Q: Do I need to take Bemolan at the exact same time every day?

Patient information generally references the need for regular dosing intervals and advises against exceeding the maximum daily frequency. The official timing advice focuses primarily on the dose's relationship to meals and bedtime.


Q: Is there a need to adjust my lifestyle while on Bemolan?

Patient information often references lifestyle factors that can support the medicine's action. These commonly include avoiding smoking and alcohol, avoiding lying down immediately after eating, and managing body weight.

How should Bemolan be stored and disposed of?

Official Storage and Disposal Requirements

Bemolan (Magaldrate) must be stored according to regulatory requirements to ensure its stability and potency.

Storage & Handling Requirement Official Classification
Temperature Range Store at controlled room temperature (typically 15 C to 30 C / 59 F to 86 F)
Handling Prohibition Do Not Freeze
Environmental Protection Protect from light and moisture
Container Integrity Keep the product in the original container, tightly closed
Child Safety Keep out of the sight and reach of children

Regulatory documents specify that the product must be discarded after its expiration date. Medicines should not be disposed of via wastewater or household waste, but must be deposited at a pharmacy collection point or other official drug take-back location to comply with environmental regulations for unused pharmaceuticals.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bemolan found in:

A-Z Index: